mRNA LNP Services

Sophia provides mRNA LNP CDMO Services for sponsors developing messenger RNA therapeutics, mRNA vaccines, personalised cancer vaccines, infectious disease vaccines, protein replacement products, rare disease programmes, gene editing payloads, immunology products, oncology immunotherapies, self-amplifying RNA interface programmes, circular RNA interface programmes, and lipid nanoparticle drug delivery systems.

mRNA LNP products are elegant because the core idea is almost brutally simple: deliver an RNA instruction into a cell and let the cell produce the protein. The hard part is everything else. The RNA must be designed correctly, transcribed cleanly, capped properly, purified deeply, protected from degradation, encapsulated into lipid nanoparticles, delivered into the right tissue, released into the cytosol, translated efficiently, tolerated immunologically, filled aseptically, shipped cold or frozen where needed, and tested with serious analytical depth.

That is why mRNA LNP CDMO Services require more than RNA synthesis. They require a complete product system: template DNA, in vitro transcription, capping, poly(A) strategy, nucleoside modification, purification, double-stranded RNA impurity control, lipid selection, nanoparticle assembly, particle analytics, encapsulation efficiency, sterile filtration feasibility, formulation, stability, fill-finish interface, GMP/GMP-like documentation, and scale-up.

Sophia supports mRNA LNP programmes through RNA process development, LNP formulation, analytical development, sterile product interface, stability, quality documentation, and European execution through state-of-the-art facilities in Spain and Switzerland. The brand logic is quiet but important: these products require exact science, controlled infrastructure, and calm technical execution. Not noise. Not theatre. Precision.

The goal is direct: turn RNA sequence into a stable, deliverable, controlled mRNA LNP product.

Why mRNA LNP Products Matter

mRNA LNP products matter because they allow medicine to use the body’s own cells as temporary protein factories. Instead of manufacturing a protein outside the body and delivering that protein directly, an mRNA product delivers the code for the protein. The cell reads the message, produces the protein, and the therapeutic or immune effect follows.

This creates major development possibilities:

• Infectious disease vaccines
• Cancer vaccines
• Personalised neoantigen vaccines
• Protein replacement therapies
• Secreted therapeutic proteins
• Intracellular protein expression
• Gene editing enzyme delivery
• Base editor and prime editor payload delivery
• CAR or immune-cell programming concepts
• Tolerogenic immunology products
• Regenerative medicine signals
• Rare disease programmes
• Combination RNA payloads
• Self-amplifying RNA interface products
• Circular RNA interface products

The value is speed and programmability. Once the platform is established, changing the encoded protein can be faster than rebuilding an entire biologics process. That has made mRNA one of the defining modern therapeutic modalities.

The difficulty is that RNA is fragile and biologically loud. It can degrade. It can trigger innate immune sensors. It can form unwanted double-stranded RNA byproducts. It can be hard to deliver. It can lose potency during storage. LNPs can aggregate, leak RNA, change particle size, oxidise, hydrolyse, or behave differently after freezing. A product can look promising in discovery and still fail because the manufacturing process cannot make it cleanly and consistently.

A serious mRNA LNP CDMO Services programme must therefore connect design, process, formulation, analytics, and quality from the start.

A Short History of mRNA Medicines

The concept of using mRNA as medicine grew from basic molecular biology. Messenger RNA is the transient instructional molecule between DNA and protein. For years, that made it attractive but frustrating. It was unstable, immunogenic, and difficult to deliver. Early work showed promise, but the product category needed better RNA chemistry, cleaner manufacturing, and better delivery systems.

Three developments changed the field.

First, RNA design improved. Cap structures, untranslated regions, codon optimisation, poly(A) tails, and modified nucleosides helped control stability, translation, and immune recognition. Second, purification improved. Removing process impurities and double-stranded RNA byproducts became central to tolerability and performance. Third, lipid nanoparticles matured into a practical delivery system for nucleic acids. Ionisable lipids, helper lipids, cholesterol, PEG-lipids, ethanol mixing, and controlled nanoparticle assembly turned RNA delivery into a manufacturable field.

mRNA vaccines then moved the modality from specialist discussion to public awareness. But vaccines are only one part of the category. The broader field now includes oncology, rare disease, gene editing, immune modulation, personalised medicine, protein replacement, and next-generation RNA formats.

The historical lesson is clear: mRNA became powerful when biology, chemistry, formulation, and manufacturing finally started working together.

The Biology and Chemistry of mRNA

An mRNA product contains several functional regions. The 5′ cap supports translation initiation and helps the cell recognise the RNA as a proper message. The 5′ untranslated region influences translation efficiency. The coding sequence encodes the target protein. The 3′ untranslated region can affect stability and translation. The poly(A) tail helps protect the RNA and support translation. Nucleoside modifications may be used to alter stability, reduce innate immune stimulation, or improve expression.

Each region can affect product performance. A cap problem can reduce translation. A weak untranslated region can lower expression. A poor coding sequence can reduce protein output. A short or inconsistent poly(A) tail can change stability. Unwanted double-stranded RNA impurities can increase immune activation. Truncated RNA can create inconsistent translation. Residual DNA template, enzymes, nucleotides, salts, solvents, or proteins can create impurity concerns.

The mRNA is made through in vitro transcription, usually from a DNA template. RNA polymerase produces the transcript from the template. Capping may occur co-transcriptionally or enzymatically after transcription. The product is then treated, purified, concentrated, and formulated.

The chemistry looks like a controlled transcription reaction. The product behaves like an information-bearing macromolecule that must survive manufacturing and reach the cytosol. That duality defines mRNA LNP CDMO Services.

The Chemistry of Lipid Nanoparticles

Lipid nanoparticles protect and deliver mRNA. A typical LNP contains an ionisable lipid, helper phospholipid, cholesterol, and PEG-lipid. Each component has a role.

The ionisable lipid is usually neutral at physiological pH but becomes positively charged in acidic conditions during formulation or endosomal processing. It helps complex the RNA during assembly and supports endosomal escape after cellular uptake. The helper phospholipid contributes membrane structure. Cholesterol supports particle stability and membrane behaviour. PEG-lipid helps control particle size and reduces aggregation during formulation, but excessive PEG-lipid can affect uptake and biological performance.

LNP assembly is usually performed by rapidly mixing an ethanolic lipid phase with an aqueous RNA phase under controlled conditions. Parameters such as flow rate, mixing ratio, lipid concentration, RNA concentration, N/P ratio, pH, buffer, temperature, and post-mixing processing affect particle size, polydispersity, encapsulation efficiency, stability, and potency.

The LNP is not just packaging. It is part of the drug product. Change the lipid composition and the biological distribution can change. Change particle size and uptake can change.

Change PEG-lipid and circulation or uptake can change. Change formulation buffer and stability can change.

A successful mRNA product depends on the RNA and the LNP behaving as one system.

mRNA LNP Product Types Supported

Sophia supports mRNA LNP CDMO Services across multiple therapeutic and product categories.

Vaccine programmes may include infectious disease vaccines, multivalent vaccines, seasonal vaccine updates, pandemic preparedness platforms, personalised cancer vaccines, shared tumour antigen vaccines, neoantigen vaccines, dendritic-cell-targeting products, and combination immunotherapy products.

Therapeutic programmes may include protein replacement, secreted protein expression, intracellular protein expression, cytokine expression, antibody expression, enzyme replacement concepts, rare disease protein restoration, immune tolerance products, regenerative factors, and metabolic disease products.

Gene editing programmes may include mRNA encoding Cas nucleases, base editors, prime editors, recombinases, transposases, zinc finger nucleases, TALENs, or other editing proteins. These programmes may require co-delivery with guide RNA, template DNA, siRNA, or other nucleic acid components.

Advanced RNA interface programmes may include self-amplifying RNA, trans-amplifying RNA, circular RNA-adjacent development, modified mRNA, long mRNA, multi-open-reading-frame RNA concepts, and combination RNA payloads.

Research and translational programmes may include discovery-grade mRNA, preclinical LNP material, toxicology batch planning, GMP/GMP-like clinical candidate supply, analytical method development, formulation screening, stability studies, and tech transfer.

The common requirement is controlled RNA expression through a deliverable particle.

Sequence, Construct, and Template Strategy

Sophia supports mRNA sequence, construct, and template strategy. This includes codon optimisation, open reading frame review, untranslated region selection, cap strategy, poly(A) tail design, modified nucleoside strategy, GC content, secondary structure, protein expression goal, antigen design, signal peptide review, secretion strategy, transmembrane protein expression, immunogenicity intent, and manufacturability.

The DNA template is a critical starting material. It may be produced as plasmid DNA, PCR-derived template, enzymatically generated template, or other defined DNA material depending on stage and product design. Template design affects transcription efficiency, RNA length, poly(A) consistency, and impurity profile.

For vaccines, antigen sequence design may include prefusion stabilisation, signal sequences, membrane anchoring, secretion, multivalent antigen design, or epitope optimisation. For protein replacement, the coding sequence must support correct protein expression and activity. For gene editing, long coding sequences and high expression demands can complicate RNA synthesis and LNP formulation.

A weak template creates weak RNA. A weak RNA creates a weak LNP product. Development begins upstream of the transcript.

In Vitro Transcription

Sophia supports in vitro transcription process development for mRNA products, including template input, RNA polymerase, nucleotide concentrations, modified nucleotides, reaction buffer, magnesium, temperature, reaction time, co-transcriptional capping, enzyme quality, scale, yield, impurity profile, and reaction termination.

The IVT process must balance yield and quality. Higher yield is not useful if impurity burden increases. Long transcripts may be harder to produce cleanly. Modified nucleotides may alter reaction efficiency. Co-transcriptional capping can simplify the workflow but requires cap analogue control. Enzymatic capping can improve certain attributes but adds process steps.

IVT impurities may include template DNA, enzymes, residual nucleotides, abortive transcripts, truncated RNA, double-stranded RNA, uncapped RNA, incorrectly capped RNA, residual proteins, salts, and process-related byproducts. The process should be developed with purification and analytics in mind.

The mRNA reaction is not just a production step. It is the origin of the drug substance quality profile.

Capping, Poly(A), and RNA Integrity

The 5′ cap and poly(A) tail are central to mRNA function. Sophia supports capping strategy, cap efficiency testing, Cap 1 considerations, enzymatic capping interface, co-transcriptional capping, poly(A) design, poly(A) tail consistency, RNA length integrity, truncated transcript control, and expression-related analytics.

Capping affects translation and immune recognition. Incomplete capping can reduce expression and increase unwanted immune activation. Poly(A) tail length can affect stability and translation. Poly(A) may be encoded in the DNA template or added enzymatically depending on product strategy.

RNA integrity must be monitored because degradation, truncation, or cleavage can reduce potency and create product heterogeneity. Long mRNA transcripts are especially vulnerable to handling stress. RNase control, low-biocontamination workflows, proper storage, and controlled processing are essential.

RNA has a dramatic personality. It can look fine until it suddenly does not. The process needs to treat it accordingly.

Purification and dsRNA Impurity Control

Sophia supports mRNA purification and impurity control, including removal of template DNA, proteins, enzymes, residual nucleotides, salts, small molecules, truncated transcripts, double-stranded RNA impurities, uncapped RNA, aggregates, endotoxin where relevant, bioburden, and process-related contaminants.

Purification strategies may include DNase treatment, chromatography, cellulose-based methods, tangential flow filtration, ultrafiltration/diafiltration, precipitation where appropriate, desalting, buffer exchange, and sterile filtration feasibility review.

Double-stranded RNA impurity control is especially important because dsRNA can trigger innate immune pathways and affect tolerability and translation. Purification must be designed to remove dsRNA while preserving full-length mRNA. This can be challenging because the desired product and impurities may share similar size, charge, and chemical properties.

For personalised or rapid-cycle products, purification must be fast and robust. For large-scale products, cost, yield, resin or membrane capacity, and reproducibility matter. For long mRNA or self-amplifying RNA, purification becomes even more demanding.

A clean mRNA product is not just full-length. It is full-length, properly capped, low in dsRNA, low in DNA, low in process impurities, and suitable for encapsulation.

LNP Formulation and Encapsulation

Sophia provides mRNA LNP CDMO Services for lipid nanoparticle formulation and encapsulation. This includes lipid selection, lipid ratio, ionisable lipid strategy, helper lipid, cholesterol, PEG-lipid, ethanol mixing, aqueous buffer selection, pH, N/P ratio, flow-rate ratio, total flow rate, particle size control, polydispersity, encapsulation efficiency, residual ethanol removal, buffer exchange, concentration, sterile filtration feasibility, and final bulk handling.

Formulation is where mRNA becomes a deliverable product. The RNA must be encapsulated efficiently without damaging the transcript. The particle must be the right size and distribution. It must protect RNA from degradation. It must support cellular uptake and endosomal release. It must remain stable through storage, shipping, thawing, and administration.

Small process changes can create meaningful differences. Mixing conditions affect particle size. Lipid composition affects potency and tolerability. Buffer affects stability. Residual ethanol must be controlled. TFF processing can affect particle concentration and integrity. Filtration can remove aggregates but may reduce yield or alter particles.

LNP formulation is not a final polish. It is core manufacturing.

LNP Analytics and Particle Characterisation

Sophia supports analytical development for mRNA LNP products, including particle size, polydispersity, zeta potential, encapsulation efficiency, RNA concentration, lipid content, lipid impurities, residual ethanol, pH, osmolality, sterility or bioburden, endotoxin, RNA integrity, dsRNA, residual DNA, potency, identity, stability, and release specifications.

Methods may include dynamic light scattering, nanoparticle tracking analysis, RiboGreen or equivalent encapsulation assays, HPLC or LC-MS lipid analysis, capillary electrophoresis, agarose gel, HPLC RNA methods, qPCR or ddPCR for residual DNA where relevant, UV spectroscopy, pH, osmolality, residual solvent testing, endotoxin testing, sterility strategy, and cell-based expression assays.

Particle analytics must connect to performance. A particle can have a nice size and poor potency. Encapsulation can be high while RNA integrity is weak. RNA can be intact but inaccessible. Potency can be strong at time zero and collapse after freeze-thaw. Orthogonal testing is essential.

The product is a nanoparticle containing RNA. The analytics must see both.

Potency and Expression Assays

Sophia supports potency and expression assay strategy for mRNA LNP programmes. Potency may be assessed through protein expression, antigen expression, enzymatic activity, reporter expression, cell-based transfection, immune activation profile, target-cell uptake, translated protein identity, and functional activity of the encoded protein.

For vaccine products, potency may relate to antigen expression and immunological readouts during development. For protein replacement products, potency may relate to expression of functional protein. For gene editing products, potency may require expression of editing machinery and editing outcome assays. For personalised cancer vaccines, potency and identity strategy must fit rapid manufacturing and sequence-specific product release.

Potency assays must evolve as the programme matures. Early assays may be exploratory. Later assays should become more robust, reproducible, and connected to release or comparability. The assay should answer the real question: does this mRNA LNP product deliver an instruction that cells can read?

Expression is the point. Everything else supports that.

Formulation, Storage, and Stability

Sophia supports formulation and stability development for mRNA LNP products across frozen, refrigerated, lyophilised, liquid, and clinical supply formats.

mRNA LNP stability risks include RNA degradation, hydrolysis, oxidation, lipid degradation, particle aggregation, RNA leakage, encapsulation loss, pH drift, potency loss, freeze-thaw damage, cryoconcentration, container interaction, and lipid nanoparticle fusion or instability. Formulation variables may include buffer, pH, salt, sugars, cryoprotectants, lyoprotectants, surfactants where appropriate, antioxidant strategy, lipid quality, concentration, and container closure.

Frozen storage is common for many RNA LNP products, but it adds operational complexity. Refrigerated or lyophilised formats may be commercially attractive but require substantial development. Lyophilisation must preserve particle size, encapsulation, RNA integrity, reconstitution, potency, residual moisture, and appearance. Not every LNP wants to be lyophilised. Some behave. Some kick off.

Stability testing should include real storage conditions, accelerated conditions, freeze-thaw, shipping simulation, thawed hold time, in-use stability, and compatibility with final presentation.

The goal is not a product that survives one perfect lab run. The goal is a product that survives development reality.

Sterile Fill-Finish Interface

mRNA LNP products usually require sterile injectable drug product workflows. Sophia supports sterile fill-finish interface planning for vials, prefilled syringes where appropriate, frozen drug product, liquid drug product, lyophilised drug product, aseptic filling, sterile filtration feasibility, container closure integrity, visual inspection, extractables and leachables, cold-chain planning, and clinical supply readiness.

Sterile filtration can be challenging for nanoparticles because filter compatibility, particle size, adsorption, pressure, yield loss, and particle change must be evaluated. Aseptic processing may be required where filtration is not straightforward. Container selection matters because particles can interact with glass, stoppers, silicone oil, tubing, bags, filters, and filling equipment.

Fill-finish also has to respect temperature and time. If the product must remain frozen or cold, the drug product process must be designed around that condition. If the product is lyophilised, the fill volume, freezing profile, cycle, and reconstitution must preserve particle quality.

A good mRNA LNP bulk can still fail at drug product stage. The interface has to be designed early.

Personalised and Rapid-Cycle mRNA Products

Sophia supports development strategy for personalised mRNA products, including personalised cancer vaccines, neoantigen vaccines, patient-specific sequence workflows, rapid manufacturing, sequence-specific release strategy, analytical platform methods, template generation, IVT, purification, LNP formulation, fill-finish coordination, and batch documentation.

Personalised mRNA products create a different manufacturing rhythm. Each patient or small group may require a unique sequence. The process must be flexible, fast, and controlled. Analytical methods may need to verify identity and quality without building a bespoke full method from scratch for every sequence. Documentation must support traceability and release under compressed timelines.

This is where state-of-the-art European infrastructure matters. Spain and Switzerland give Sophia a disciplined platform for advanced development, analytical control, and clinical-stage coordination without making the manufacturing model feel chaotic. Personalised medicine does not mean personalised disorder.

The product may be custom. The process must be standardised.

saRNA and Circular RNA Interface

Sophia supports interface planning for self-amplifying RNA and circular RNA-adjacent programmes. These are not identical to conventional mRNA, but they share important process and analytical questions.

Self-amplifying RNA can encode replication machinery that amplifies RNA intracellularly, potentially lowering dose. It is usually longer than conventional mRNA, which can make synthesis, integrity, purification, and LNP formulation more difficult. Circular RNA may offer improved stability and different translation behaviour, but circularisation, purification, linear RNA removal, and identity testing create unique requirements.

Sophia’s mRNA LNP CDMO Services can support these programmes through RNA design review, template strategy, purification planning, LNP formulation interface, particle analytics, stability, and documentation. Dedicated process development is needed because long RNA, replicon RNA, and circular RNA do not behave exactly like standard mRNA.

The RNA family is expanding. The development discipline remains the same: define the molecule, control the process, prove the product.

European Facilities, Spain, and Switzerland

mRNA LNP development needs infrastructure that can handle RNA fragility, nanoparticle precision, sterile product expectations, analytical depth, and GMP/GMP-like documentation. Sophia’s European execution model is built around state-of-the-art facilities in Spain and Switzerland, giving programmes access to a high-discipline technical environment for RNA process development, LNP formulation, analytical characterisation, formulation stability, and clinical supply planning.

Spain supports applied process work, formulation development, and flexible programme execution within a strong European life science setting. Switzerland strengthens the platform with precision manufacturing culture, analytical seriousness, and quality-led documentation.

The combination gives Sophia a distinctive European brand position: advanced RNA products developed with calm technical control, not inflated promises.

By this stage, the proper phrase is simple: the product must be fit for purpose. Sequence-correct. Particle-controlled. Potent. Stable. Documented. Shippable. No faff.

GMP, CMC, and Documentation

Sophia supports GMP/GMP-like and CMC documentation for mRNA LNP CDMO Services, including DNA template records, raw material controls, IVT process description, capping strategy, purification process, impurity control strategy, LNP formulation process, lipid specifications, encapsulation data, particle analytics, RNA integrity, dsRNA control, residual DNA control, potency assay strategy, sterile product interface, formulation report, stability protocol, batch records, CoA, deviation handling, change control, and tech transfer package.

For mRNA vaccines and therapeutics, the CMC package must explain both drug substance and drug product logic. The RNA sequence, template, IVT process, capping, purification, and impurity controls define the active RNA. The LNP composition, mixing process, encapsulation, particle attributes, sterile handling, and formulation define the deliverable drug product.

Comparability can be important if sequence changes, lipid suppliers change, mixing equipment changes, scale changes, purification changes, formulation changes, or fill-finish conditions change. The programme should build enough analytical understanding to support development without panic at each transition.

Documentation is how the platform becomes trustworthy.

Why Sophia for mRNA LNP CDMO Services

Sophia supports mRNA LNP programmes through RNA process development, LNP formulation, particle analytics, potency strategy, sterile product interface, formulation stability, European facility execution, and GMP/GMP-like documentation.

The service includes:

• mRNA LNP programme review
• mRNA sequence and construct developability
• DNA template strategy
• IVT process development
• Capping and poly(A) strategy
• Modified nucleoside support
• RNA purification and dsRNA impurity control
• Residual DNA, enzyme, nucleotide, and process impurity strategy
• Lipid nanoparticle formulation
• Ionisable lipid, helper lipid, cholesterol, and PEG-lipid strategy
• Particle size, PDI, encapsulation efficiency, and zeta potential analytics
• LNP concentration, buffer exchange, and sterile filtration feasibility
• Potency and expression assay strategy
• Frozen, liquid, and lyophilised formulation development
• Sterile fill-finish interface
• Spain and Switzerland-linked European technical execution
• GMP/GMP-like documentation
• Scale-up and tech transfer

The platform is suited to sponsors who need RNA sequence, nanoparticle formulation, analytical control, sterile product readiness, and stability to work as one integrated product system.

Technical Service Summary

Sophia provides mRNA LNP CDMO Services for mRNA vaccines, personalised cancer vaccines, protein replacement products, rare disease mRNA, gene editing mRNA, Cas nuclease mRNA, base editor mRNA, prime editor mRNA, self-amplifying RNA interface programmes, circular RNA interface programmes, LNP formulation, RNA purification, sterile injectable products, and clinical-stage RNA manufacturing.

Relevant technical needs include DNA template strategy, IVT, capping, poly(A), modified nucleosides, dsRNA removal, RNA integrity testing, LNP formulation, encapsulation efficiency, particle size analytics, lipid analysis, potency assays, formulation, lyophilisation, sterile fill-finish interface, stability, GMP/GMP-like records, and scale-up.

The service is intended for products where RNA design, delivery chemistry, particle control, potency, and stability define the medicine.

FAQ: mRNA LNP CDMO Services

1. What are mRNA LNP CDMO Services?

mRNA LNP CDMO Services support development and manufacturing of messenger RNA products formulated in lipid nanoparticles, including IVT, capping, purification, LNP formulation, analytics, formulation, stability, sterile product interface, and documentation.

2. What is an mRNA LNP product?

An mRNA LNP product contains messenger RNA encapsulated in lipid nanoparticles. The LNP protects the RNA and helps deliver it into cells, where the RNA can be translated into protein.

3. What products can use mRNA LNP technology?

mRNA LNP technology can support vaccines, cancer vaccines, protein replacement, rare disease therapies, gene editing payload delivery, immune modulation, regenerative signals, and personalised medicine products.

4. How is mRNA manufactured?

mRNA is commonly manufactured by in vitro transcription from a DNA template, followed by capping, purification, impurity removal, concentration, and formulation.

5. Why are lipid nanoparticles needed?

LNPs protect RNA from degradation, help cellular uptake, support endosomal escape, and make RNA delivery practical for therapeutic or vaccine applications.

6. What analytics are used for mRNA LNP products?

Analytics may include RNA integrity, capping efficiency, poly(A) assessment, dsRNA testing, residual DNA, particle size, PDI, encapsulation efficiency, lipid content, residual ethanol, pH, osmolality, potency, endotoxin, sterility strategy, and stability.

7. What is dsRNA impurity control?

Double-stranded RNA impurities can form during IVT and may increase innate immune activation. Purification and analytical methods are used to reduce and monitor dsRNA.

8. Can mRNA LNP products be lyophilised?

Some mRNA LNP products may be lyophilised, but cycle development must preserve particle size, encapsulation, RNA integrity, potency, reconstitution, and stability.

9. Can Sophia support personalised mRNA vaccines?

Yes. Sophia supports personalised mRNA vaccine development strategy, including sequence-specific workflows, template generation, IVT, purification, LNP formulation, analytical platform methods, documentation, and clinical supply planning.

10. What should sponsors provide to begin an mRNA LNP project?

Useful starting information includes mRNA sequence, encoded protein, template strategy, UTR and poly(A) design, modification plan, intended route, LNP composition if known, existing expression data, scale target, formulation needs, stability goals, and regulatory stage.

Conclusion

Sophia provides mRNA LNP CDMO Services for sponsors developing mRNA vaccines, personalised cancer vaccines, protein replacement therapies, rare disease products, gene editing mRNA, self-amplifying RNA interface products, circular RNA interface products, and lipid nanoparticle delivery systems.

mRNA LNP products are powerful because they turn genetic information into temporary protein expression inside cells. They are difficult because RNA design, IVT, capping, purification, dsRNA removal, LNP formulation, encapsulation, potency, sterile handling, stability, and documentation all have to work together. A weak RNA cannot be rescued by a beautiful particle. A strong RNA can fail in a poor LNP. A good LNP can still fail at fill-finish or storage.

A complete mRNA LNP CDMO Services programme may include sequence review, DNA template strategy, IVT process development, capping, poly(A), RNA purification, dsRNA impurity control, LNP formulation, particle analytics, potency testing, formulation, lyophilisation interface, sterile fill-finish planning, stability, GMP/GMP-like records, and scale-up through Sophia’s state-of-the-art European facilities in Spain and Switzerland.

For sponsors developing mRNA therapeutics, mRNA vaccines, LNP-formulated RNA, gene editing mRNA, personalised neoantigen vaccines, or advanced RNA delivery platforms, Sophia provides a controlled route from RNA sequence to stable, deliverable product.

Email our team at info@sophiacdmo.com